305- Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting
enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial
infarction. J Am Coll Cardiol. 2003;42(2):201–8. - Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten
J. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis.
2002;40(5):1023–9. - McCullough PA, Sandberg KR, Yee J, Hudson MP. Mortality benefit of angiotensin-converting
enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin-
Angiotensin- Aldosterone Syst. 2002;3(3):188–91. - Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y. Candesartan, an
angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic
haemodialysis—a randomized study. Nephrol Dial Transplant. 2006;21(9):2507–12. - Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of
angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis:
an open-label randomized controlled trial. Am J Kidney Dis. 2008;52(3):501–6. - Iseki K, Arima H, Kohagura K, Komiya I, Ueda S, Tokuyama K, Shiohira Y, Uehara H, Toma
S, Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group. Effects
of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients
with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant.
2013;28(6):1579–89. - Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM,
Akiba T, Kurokawa K, Ramirez S, Young EW. Diuretic use, residual renal function, and mor-
tality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study
(DOPPS). Am J Kidney Dis. 2007;49(3):426–31. - Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel
blocker use and mortality among patients with end-stage renal disease. Kidney Int.
2002;61(6):2157–64. - Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovas-
cular events in hypertensive haemodialysis patients. Nephrol Dial Transplant.
2008;23(11):3605–12. - Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H. Comparison of the
effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their
combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent
onset hemodialysis therapy. Ther Apher Dial. 2004;8(4):320–7. - Kuriyama S, Yokoyama K, Hara Y, Sugano N, Yokoo T, Hosoya T. Effect of aliskiren in chronic
kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized
controlled multicenter study. Clin Exp Nephrol. 2014;18(5):821–30. - Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin
PY. Safety of low-dose spironolactone administration in chronic haemodialysis patients.
Nephrol Dial Transplant. 2003;18(11):2359–63. - Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL. Is spironolactone safe for
dialysis patients? Nephrol Dial Transplant. 2003;18(11):2364–8. - Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H,
Ohmura H, Shio N. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodi-
alysis patients. Cardiology. 2009;114(1):32–8. - Foley RN, Herzog CA, Collins AJ, United States Renal Data System. Blood pressure and long-
term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney
Int. 2002;62(5):1784–90. - Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A. Dilated cardio-
myopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-
controlled trial. J Am Coll Cardiol. 2001;37(2):407–11.
18 Treatment of Hypertension in Light of the New Guidelines: Pharmacologic...